Does the Frequency of Molecular Monitoring After Tyrosine Kinase Inhibitor Discontinuation Affect Outcomes of Patients With Chronic Myeloid Leukemia?

Cancer - United States
doi 10.1002/cncr.30608
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Tyrosine Kinase Inhibitor Sequencing in Patients With Chronic Myeloid Leukemia

Oncology and Therapy
Oncology
2019English

Effect of Tyrosine Kinase Inhibitor in Patients With Chronic Myeloid Leukemia (Cytogenetic, Molecular Response) in Mosul

Annals of the College of Medicine, Mosul
2018English

Future Perspectives of Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia

Chemotherapy: Open Access
2017English

Managing Chronic Myeloid Leukemia Patients Intolerant to Tyrosine Kinase Inhibitor Therapy

Blood Cancer Journal
OncologyHematology
2012English

The Impact of BCR-ABL1 Transcript Type on Tyrosine Kinase Inhibitor Responses and Outcomes in Patients With Chronic Myeloid Leukemia

Cancer
Cancer ResearchOncology
2018English

Planned Pregnancy in Female Patients With Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy

Oncologist
Cancer ResearchMedicineOncology
2019English

Outcome of Patients With Chronic Myeloid Leukemia With Multiple ABL1 Kinase Domain Mutations Receiving Tyrosine Kinase Inhibitor Therapy

Haematologica
Hematology
2011English

Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Recommendations for Clinical Practice From the French Chronic Myeloid Leukemia Study Group

Cancer
Cancer ResearchOncology
2018English

Current Event-Free Survival After Sequential Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia

Cancer
Cancer ResearchOncology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy